(PS) CSPC Dophen Corporation v. Hu

CourtDistrict Court, E.D. California
DecidedJuly 20, 2020
Docket2:17-cv-01895
StatusUnknown

This text of (PS) CSPC Dophen Corporation v. Hu ((PS) CSPC Dophen Corporation v. Hu) is published on Counsel Stack Legal Research, covering District Court, E.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
(PS) CSPC Dophen Corporation v. Hu, (E.D. Cal. 2020).

Opinion

1 2 3 4 5 6 7 8 UNITED STATES DISTRICT COURT 9 FOR THE EASTERN DISTRICT OF CALIFORNIA 10 11 CSPC DOPHEN CORPORATION, No. 2:17-cv-1895 MCE DB PS 12 Plaintiff, 13 v. ORDER AND FINDINGS AND RECOMMENDATIONS 14 ZHIXIANG HU,

15 Defendant. 16 17 Defendant and counterclaimant, Dr. Zhixiang Hu, Ph.D., (“Dr. Hu”), is proceeding in this 18 matter pro se. (ECF No. 68.) Accordingly, this action has been referred to the undersigned 19 pursuant to Local Rule 302(c)(21) and 28 U.S.C. § 636(b)(1). Pending before the undersigned are 20 Dr. Hu’s motion for leave for alternative service of process, plaintiff CSCP Dophen Corporation’s 21 partial motion to dismiss Dr. Hu’s second amended counterclaim, and counter-defendant CSPC 22 Pharmaceutical Group Limited’s motion to dismiss. (ECF Nos. 218, 227, 236.) 23 For the reasons explained below, Dr. Hu’s motion for leave for alternative service of 24 process is granted. Also, the undersigned recommends that the motions to dismiss be granted 25 without further leave to amend. 26 BACKGROUND 27 Plaintiff CSPC Dophen Corporation, (“CSPC Dophen”), commenced this action on 28 September 11, 2017. (ECF No. 1.) Plaintiff filed a third amended complaint on May 7, 2019. 1 (ECF No. 190.) Therein, plaintiff alleges that CSPC Dophen is a pharmaceutical and 2 development company based in Sacramento, California. (Third Am. Compl. (ECF No. 190) at 3 2.1) Plaintiff hired defendant Dr. Hu in October of 2011, as Director of CSPC Dophen’s Research 4 Laboratory. (Id. at 3.) Dr. Hu signed a Non-Disclosure Agreement and a Policy of Conflict of 5 Interest as part of that employment. (Id. at 3-4.) 6 However, on April 24, 2014, Dr. Hu incorporated a competing entity named Dophen 7 Biomed, Inc., with the same address as CSPC Dophen. (Id. at 4.) Dr. Hu also established a bank 8 account and deposited plaintiff’s money into that account. (Id. at 5.) And in April of 2017, Dr. 9 Hu filed an Investigational New Drug application with the Food and Drug Administration 10 (“FDA”) using plaintiff’s name without plaintiff’s consent. (Id.) Plaintiff terminated Dr. Hu’s 11 employment on July 21, 2017. (Id. at 6.) 12 Based on these allegations the third amended complaint asserts causes of action for breach 13 of contract, breach of the duty of loyalty, violation of the Defend Trade Secrets Act, 18 U.S.C. § 14 1832(a)(1), violation of the Lanham Act, 15 U.S.C. § 1125(a), conversion, violation of the 15 California Comprehensive Computer Data Access and Fraud Act, California Penal Code § 502, 16 unfair competition, and defamation. (Id. at 7-16.) 17 On November 24, 2019, Dr. Hu filed a motion seeking leave for alternative service of 18 process on several counter defendants. (ECF No. 218.) On December 6, 2019, Dr. Hu filed a 19 motion for a seven-day extension of time to file a second amended counterclaim.2 (ECF No. 20 223.) Dr. Hu filed a second amended counterclaim on December 10, 2019. (ECF No. 224.) 21 On December 23, 2019, plaintiff filed a partial motion to dismiss pursuant to Rule 12(6) 22 and to strike pursuant to Rule 12(f) of the Federal Rules of Civil Procedure. (ECF No. 227.) On 23 January 10, 2020, Dr. Hu filed an opposition to the motion to dismiss and plaintiff filed an 24 opposition to Dr. Hu’s motion for leave for alternative service of process on the counter- 25 //// 26 1 Page number citations such as this one are to the page number reflected on the court’s CM/ECF 27 system and not to page numbers assigned by the parties.

28 1 defendants. (ECF Nos. 230 & 231.) The parties filed replies on January 17, 2020. (ECF Nos. 2 232 & 234.) 3 On January 21, 2020, counter-defendant CSPC Pharmaceutical Group Limited, (“CSPC 4 Limited”), filed a motion to dismiss for lack of jurisdiction pursuant to Rule 12(b)(2). (ECF No. 5 236.) Dr. Hu filed an opposition on February 28, 2020. (ECF No. 249.) CSPC Limited filed a 6 reply on March 6, 2020. (ECF No. 251.) 7 STANDARDS 8 I. Legal Standards Applicable to Motions to Dismiss Pursuant to Rule 12(b)(2) 9 Federal Rule of Civil Procedure 12(b)(2) provides that “[a] defendant may move, prior to 10 trial, to dismiss the complaint for lack of personal jurisdiction.” Data Disc, Inc. v. Systems 11 Technology Associates, Inc., 557 F.2d 1280, 1285 (9th Cir. 1977). “Where a defendant moves to 12 dismiss a complaint for lack of personal jurisdiction, the plaintiff bears the burden of 13 demonstrating that jurisdiction is appropriate.” Schwarzenegger v. Fred Martin Motor Co., 374 14 F.3d 797, 800 (9th Cir. 2004). However, “in the absence of an evidentiary hearing, the plaintiff 15 need only make a prima facie showing of jurisdictional facts.” Sher v. Johnson, 911 F.2d 1357, 16 1361 (9th Cir. 1990). 17 II. Legal Standards Applicable to Motions to Dismiss Pursuant to Rule 12(b)(6) 18 The purpose of a motion to dismiss pursuant to Rule 12(b)(6) is to test the legal 19 sufficiency of the complaint. N. Star Int’l v. Ariz. Corp. Comm’n, 720 F.2d 578, 581 (9th Cir. 20 1983). “The rule applies equally to a counterclaim.” Hana Financial, Inc. v. Hana Bank, 500 21 F.Supp.2d 1228, 1232 (C.D. Cal. 2007). “Dismissal can be based on the lack of a cognizable 22 legal theory or the absence of sufficient facts alleged under a cognizable legal theory.” Balistreri 23 v. Pacifica Police Dep’t, 901 F.2d 696, 699 (9th Cir. 1990). A party is required to allege “enough 24 facts to state a claim to relief that is plausible on its face.” Bell Atl. Corp. v. Twombly, 550 U.S. 25 544, 570 (2007). “A claim has facial plausibility when the plaintiff pleads factual content that 26 allows the court to draw the reasonable inference that the defendant is liable for the misconduct 27 alleged.” Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009). 28 //// 1 In determining whether a counterclaim states a claim on which relief may be granted, the 2 court accepts as true the allegations in the counterclaim and construes the allegations in the light 3 most favorable to the nonmoving party. Hishon v. King & Spalding, 467 U.S. 69, 73 (1984); 4 Love v. United States, 915 F.2d 1242, 1245 (9th Cir. 1989). In general, pro se pleadings are held 5 to less stringent standards than formal pleadings drafted by lawyers. Haines v. Kerner, 404 U.S. 6 519, 520-21 (1972). However, the court need not assume the truth of legal conclusions cast in the 7 form of factual allegations. United States ex rel. Chunie v. Ringrose, 788 F.2d 638, 643 n.2 (9th 8 Cir. 1986). 9 While Rule 8(a) does not require detailed factual allegations, “it demands more than an 10 unadorned, the defendant-unlawfully-harmed-me accusation.” Iqbal, 556 U.S. at 678. A 11 pleading is insufficient if it offers mere “labels and conclusions” or “a formulaic recitation of the 12 elements of a cause of action.” Twombly, 550 U.S. at 555; see also Iqbal, 556 U.S. at 676 13 (“Threadbare recitals of the elements of a cause of action, supported by mere conclusory 14 statements, do not suffice.”). Moreover, it is inappropriate to assume that the nonmoving party 15 “can prove facts which it has not alleged or that the defendants have violated the . . . laws in ways 16 that have not been alleged.” Associated Gen. Contractors of Cal., Inc. v. Cal.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

International Shoe Co. v. Washington
326 U.S. 310 (Supreme Court, 1945)
Mullane v. Central Hanover Bank & Trust Co.
339 U.S. 306 (Supreme Court, 1950)
Keeton v. Hustler Magazine, Inc.
465 U.S. 770 (Supreme Court, 1984)
Hishon v. King & Spalding
467 U.S. 69 (Supreme Court, 1984)
Fogerty v. Fantasy, Inc.
510 U.S. 517 (Supreme Court, 1994)
Dole Food Co. v. Patrickson
538 U.S. 468 (Supreme Court, 2003)
Watters v. Wachovia Bank, N. A.
550 U.S. 1 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Brayton Purcell LLP v. Recordon & Recordon
606 F.3d 1124 (Ninth Circuit, 2010)
James Kelley v. Rambus, Inc.
384 F. App'x 570 (Ninth Circuit, 2010)
Whittlestone, Inc. v. Handi-Craft Co.
618 F.3d 970 (Ninth Circuit, 2010)
Sanford v. MemberWorks, Inc.
625 F.3d 550 (Ninth Circuit, 2010)
Wilson v. Bradlees of New England, Inc.
250 F.3d 10 (First Circuit, 2001)
Goodyear Dunlop Tires Operations, S. A. v. Brown
131 S. Ct. 2846 (Supreme Court, 2011)
CollegeSource, Inc. v. AcademyOne, Inc.
653 F.3d 1066 (Ninth Circuit, 2011)
Mavrix Photo, Inc. v. Brand Technologies, Inc.
647 F.3d 1218 (Ninth Circuit, 2011)

Cite This Page — Counsel Stack

Bluebook (online)
(PS) CSPC Dophen Corporation v. Hu, Counsel Stack Legal Research, https://law.counselstack.com/opinion/ps-cspc-dophen-corporation-v-hu-caed-2020.